Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.
Marilina García-ArandaTeresa TéllezLauraine McKennaMaximino RedondoPublished in: Cancers (2022)
Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.
Keyphrases
- papillary thyroid
- healthcare
- endothelial cells
- squamous cell
- end stage renal disease
- nk cells
- prostate cancer
- chronic kidney disease
- randomized controlled trial
- lymph node metastasis
- clinical trial
- ejection fraction
- young adults
- prognostic factors
- newly diagnosed
- childhood cancer
- systematic review
- climate change
- binding protein
- radical prostatectomy
- patient reported
- free survival
- bioinformatics analysis